Arax Advisory Partners’s Aclaris Therapeutics ACRS Stock Holding History

Arax Advisory Partners’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.16K	Buy	+786	New	+$3.5K	﹤0.01%	4645
2026 Q1	–	Sell	-19	Closed	-$57	–	3772
2025 Q4	$57	Sell	19 -428	-96%	-$1.08K	﹤0.01%	3901
2025 Q3	$849	Buy	+447	New	+$779	﹤0.01%	3294
2024 Q4	–	Sell	-1,632	Closed	-$1.88K	–	2417
2024 Q3	$1.88K	Hold	1,632	–	–	﹤0.01%	2087
2024 Q2	$1.8K	Buy	+1,632	New	+$1.92K	﹤0.01%	2003

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Arax Advisory Partners's ACRS Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Aclaris Therapeutics (ACRS) in Q2 2026: 786 shares worth $4.16K. The stake represents ﹤0.01% of the portfolio and ranks #4645 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in ACRS as recently as Q4 2025.

Arax Advisory Partners first reported a position in ACRS in Q2 2024 and has held it in 5 quarters since. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Arax Advisory Partners held 786 shares of Aclaris Therapeutics worth $4.16K as of Q2 2026.
Aclaris Therapeutics was a new Arax Advisory Partners position in Q2 2026.
Aclaris Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4645 holding.
Arax Advisory Partners first reported a position in Aclaris Therapeutics in Q2 2024 and has held it in 5 quarters since.
148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.